2 consecutive daily limit-ups: Chongqing Re-Board Pharmaceutical Holdings: In the recent period, its operations are normal. There are no circumstances in which the internal or external operating environment has had or is expected to have any material change.

NightAirdropper · 2026-04-06T20:26:14+00:00

Everyday AI Express, on April 6th, Chongyao Holdings announced an abnormal stock trading fluctuation notice stating that the company's stock closing prices on April 2 and April 3, 2026, experienced a cumulative deviation of over 20% for two consecutive trading days, which qualifies as an abnormal stock trading fluctuation. The company has not found any recent public media reports of undisclosed significant information that could or has already had a substantial impact on the company's stock trading prices. Recently, the company's operating conditions are normal, and there are no internal or external operational environments expected to undergo or be about to undergo significant changes. Daily Economic News

NightAirdropper

2026-04-06 20:26:14

AI Express by China Business News, April 6 — Chongqing Yaokong Holding Co., Ltd. issued a notice regarding abnormal stock price fluctuations, stating that the closing price increase deviation value for its shares exceeded 20% in cumulative terms over two consecutive trading days on April 2, 2026, and April 3, 2026. This situation falls under abnormal stock trading fluctuations. The company has not found any recently reported public media coverage that might have or has already had a significant impact on the trading price of its shares due to undisclosed material information. In the near term, the company’s business operations are normal, and there is no situation in which its internal or external business environment has occurred or is expected to undergo any major changes.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes